PhRMA Sues Trump Over Medicare Drug Price Pilot — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- PhRMA filed a lawsuit asserting that the GLOBE pilot — a Medicare Part B program tying U.S. drug prices to peer countries' prices — exceeds Medicare's statutory authority
- The GLOBE pilot is not expected to have much immediate impact because the administration exempted all but a handful of companies in exchange for voluntary Medicaid MFN pricing deals
- PhRMA says voluntary agreements are acceptable but the mandatory GLOBE program must be "nipped in the bud" before it sets a wider precedent
- The Trump administration is separately drafting plans to allow temporary sales of certain previously restricted peptides as federal health officials hammer out new regulations
- Under the proposal, compounding pharmacies could dispense products marketed as new medical treatments and wellness products whose safety claims have not been fully tested
- Per the Washington Post, the peptide plan has not yet been announced and its timing remains unclear
Why it matters: PhRMA has accepted voluntary Medicaid price-control agreements while simultaneously suing to block the Trump administration from imposing the same pricing through a mandatory pilot — a dual-track strategy that preserves industry-friendly side deals while trying to constrain federal pricing authority going forward.
Ask SkimNews
